from Breakingviews:

Shire gambles AbbVie break fee on risky $5 bln deal

January 12, 2015

By Neil Unmack

The author is a Reuters Breakingviews columnist. The opinions expressed are his own.

from Breakingviews:

Review: An Icelandic tycoon’s sorry saga

December 19, 2014

By Quentin Webb

The author is a Reuters Breakingviews columnist. The opinions expressed are his own.

from Breakingviews:

Merck bets $8.4 bln on more profitable antibiotics

December 8, 2014

By Robert Cyran

The author is a Reuters Breakingviews columnist. The opinions expressed are his own.

from Breakingviews:

Pharma’s dying assets lack M&A remedy

December 5, 2014

By Neil Unmack

The author is a Reuters Breakingviews columnist. The opinions expressed are his own. 

from Breakingviews:

AstraZeneca struggles to advance value defence

November 18, 2014

By Neil Unmack

The author is a Reuters Breakingviews columnist. The opinions expressed are his own. 

from Breakingviews:

Valeant’s activist deal too clever by half

November 18, 2014

By Richard Beales and Robert Cyran

The authors are Reuters Breakingviews columnists. The opinions expressed are their own. 

from Breakingviews:

LabCorp deal tests positive for value destruction

November 3, 2014

By Robert Cyran

The author is a Reuters Breakingviews columnist. The opinions expressed are his own. 

from Breakingviews:

Amgen boss makes a prime breakup target

October 22, 2014

By Robert Cyran

The author is  a Reuters Breakingviews columnist. The opinions expressed are his own. 

from Breakingviews:

AbbVie U-turn shows Shire was mostly about tax

October 15, 2014

By Neil Unmack

The author is a Reuters Breakingviews columnist. The opinions expressed are her own.

from Breakingviews:

Tax clampdown could deter half-baked pharma M&A

September 23, 2014

By Neil Unmack and Robert Cyran

The authors are Reuters Breakingviews columnists. The opinions expressed are their own.